Literature DB >> 21717105

CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.

Fangfang Liu1, Ronggang Lang, Jing Zhao, Xinmin Zhang, Gordon A Pringle, Yu Fan, Dong Yin, Feng Gu, Zhi Yao, Li Fu.   

Abstract

The prognostic significance of tumor-associated FOXP3(+) regulatory T cells (Tregs) and CD8(+) cytotoxic T lymphocytes (CTLs) in invasive breast carcinomas is studied. Tregs and CTLs were assessed by immunohistochemistry in 1270 cases of invasive breast carcinoma for their associations with patient survival, histopathologic features, and molecular subtypes. Infiltrates of Tregs and CTLs were observed within tumor bed and in the tissue surrounding tumor. Within tumor bed, increased infiltration of Tregs and CTLs was significantly more common in those with unfavorable histologic features, including high histologic grade and negative ER and PR status. In addition, high density Treg infiltration was also associated with tumor HER2 overexpression, decreased overall survival (OS) and progression-free survival (PFS). In tissue surrounding tumor, in contrast, high CTL/Treg ratio was found to be significantly associated with improved OS and PFS. These prognostic associations were confirmed by multivariate analysis. Furthermore, the density of Treg infiltrates within tumors was inversely correlated with the prognosis of the molecular subtypes of tumors. The ratio of CTL/Treg infiltrates in the surrounding tissue was also significantly higher in luminal than non-luminal subtypes of carcinoma. The prognostic significances of Tregs and CTLs in breast carcinoma depend on their relative density and location. The density of intratumoral Treg infiltrates and the peritumoral CTL/Treg ratio are independent prognostic factors and correlated with the prognosis of the molecular subtypes of breast carcinoma, which may serve as potential target for stratifying immunotherapy to battle against the aggressive subtypes of breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717105     DOI: 10.1007/s10549-011-1647-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  111 in total

Review 1.  Epithelial ovarian cancer - more data, more questions?

Authors:  Stefanie Aust; Dietmar Pils
Journal:  Wien Med Wochenschr       Date:  2014-11-13

2.  Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats.

Authors:  Xiyuan Zhang; Katherine L Cook; Anni Warri; Idalia M Cruz; Mariana Rosim; Jeffrey Riskin; William Helferich; Daniel Doerge; Robert Clarke; Leena Hilakivi-Clarke
Journal:  Clin Cancer Res       Date:  2017-02-01       Impact factor: 12.531

3.  A comprehensive information database (CID) of breast cancer patients in China.

Authors:  Shuai Li; Li Fu
Journal:  Front Med       Date:  2012-05-08       Impact factor: 4.592

4.  Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Authors:  Lutfiye Demir; Seyran Yigit; Hulya Ellidokuz; Cigdem Erten; Isil Somali; Yuksel Kucukzeybek; Ahmet Alacacioglu; Suna Cokmert; Alper Can; Murat Akyol; Ahmet Dirican; Vedat Bayoglu; Aysegul Akder Sari; Mustafa Oktay Tarhan
Journal:  Clin Exp Metastasis       Date:  2013-07-09       Impact factor: 5.150

Review 5.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

6.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 7.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

8.  A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.

Authors:  Lisa I Greene; Tullia C Bruno; Jessica L Christenson; Angelo D'Alessandro; Rachel Culp-Hill; Kathleen Torkko; Virginia F Borges; Jill E Slansky; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2018-08-24       Impact factor: 5.852

Review 9.  Adaptive immunity programmes in breast cancer.

Authors:  Frederick S Varn; David W Mullins; Hugo Arias-Pulido; Steven Fiering; Chao Cheng
Journal:  Immunology       Date:  2016-09-20       Impact factor: 7.397

10.  Can immunity to breast cancer eliminate residual micrometastases?

Authors:  Mary L Disis; Sasha E Stanton
Journal:  Clin Cancer Res       Date:  2013-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.